Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Esperion, retaining the price target of $16.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors related to Esperion’s strategic advancements and market potential. The recent approval of NILEMDO in Canada marks a significant milestone, enhancing its global market presence as it is now approved in over 40 countries. This approval positions NILEMDO as a first-in-class oral alternative for patients with statin intolerance, which is a substantial market segment given that many patients do not achieve desired LDL-C levels with statins alone.
Moreover, the anticipated regulatory decisions in Israel and Australia/New Zealand further support the potential for global expansion. The company’s focus on non-statin lipid-lowering drugs addresses a critical need for patients who are either intolerant or refuse statins, which represents a significant opportunity. The insights shared by key opinion leaders during a recent event underscore the importance of these therapies in managing cardiovascular risks, reinforcing the commercial viability of Esperion’s products.
Pantginis covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Esperion, and Celldex. According to TipRanks, Pantginis has an average return of 5.4% and a 44.11% success rate on recommended stocks.
In another report released on November 6, Needham also maintained a Buy rating on the stock with a $4.00 price target.